UK markets closed
  • NIKKEI 225

    28,635.21
    +89.03 (+0.31%)
     
  • HANG SENG

    29,297.53
    -93.73 (-0.32%)
     
  • CRUDE OIL

    52.58
    -0.03 (-0.06%)
     
  • GOLD FUTURES

    1,839.70
    -11.20 (-0.61%)
     
  • DOW

    30,351.55
    -585.49 (-1.89%)
     
  • BTC-GBP

    22,467.54
    -1,251.24 (-5.28%)
     
  • CMC Crypto 200

    619.14
    -20.78 (-3.25%)
     
  • ^IXIC

    13,288.15
    -337.91 (-2.48%)
     
  • ^FTAS

    3,716.37
    -45.27 (-1.20%)
     

Global Chronic Kidney Disease Drugs Market to Surpass US$ 16,222.7 Million by 2027, Says Coherent Market Insights (CMI)

·4-min read

According to Coherent Market Insights, the global chronic kidney disease drugs market is estimated to be valued at US$ 12,328.2 million in 2020 and is expected to exhibit a CAGR of 4.0% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Chronic Kidney Disease Drugs Market:

Key trends in the market include rising prevalence of chronic kidney disease, product approvals & launches for the treatment of chronic kidney disease, and adoption of inorganic growth strategies by market players. For instance, according to the Quality and Outcomes Framework (QOF) and the UK Renal Registry data, the prevalence of chronic kidney disease (stage 3-5) in England was around 4.09 per 100 in people of age 18 years and above in 2018.

Key players operating in the market are focusing on novel product launches and approvals, in order to expand their product portfolio and strengthen their presence in the global market. For instance, in September 2019, Kissei Pharmaceutical Co., Ltd. and JCR Pharmaceuticals Co., Ltd. collaboratively developed and received marketing approval in Japan for Darbepoetin Alfa BS Injection, a biosimilar of darbepoetin alfa, indicated for the treatment of renal anemia in patients with chronic kidney disease (CKD).

Moreover, in November 2018, November, Kissei Pharmaceutical Co., Ltd. launched P-TOL Granules (250 mg and 500 mg) tablets indicated for the treatment of hypophosphatemia in patients with chronic kidney disease on dialysis.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1713

Furthermore, majority of the pharmaceutical manufacturers operating in the chronic kidney disease drugs market are engaged in the adoption of inorganic growth strategies such as collaborations, partnerships, and acquisitions to strengthen their market share, which is fuelling growth of the global chronic kidney disease drugs market.

Key Market Takeaways:

The global chronic kidney disease drugs market is expected to exhibit a CAGR of 4.0% during the forecast period, owing to increasing prevalence of chronic kidney disease across the globe. For instance, according to Lancet data in 2017, prevalence of chronic kidney disease in Southeast Asia was found to be 69,598,036 and total 134,459 deaths were seen due to chronic kidney disease in the same region.

Among drug type, Erythropoiesis-stimulating Agents(ESAs) segment is estimated to hold a dominant position in the global chronic kidney disease drugs market in 2020, owing to recent regulatory approvals of novel products of this drug type by key players in the global market.

Among regions, North America is estimated to hold largest market share in the global chronic kidney disease drugs market in 2020, owing to increase in awareness campaigns for chronic kidney disease, higher prevalence of chronic kidney disease and favorable reimbursement policies in the region.

Competitive Landscape:

Key players operating in the global chronic kidney disease drugs market include Amgen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, Hoffmann La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1713

Market Segmentation:

  • Global Chronic Kidney Disease Drugs Market, By Drug Type:

    • ACE Inhibitors

    • B-blockers

    • Calcium Channel Blockers

    • Loop Diuretics

    • Erythropoiesis-stimulating Agents (ESAs)

    • Phosphate Binder

    • Others

  • Global Chronic kidney Disease Drugs Market, By Route of Administration:

    • Oral

    • Intravenous

    • Subcutaneous

  • Global Chronic kidney Disease Drugs Market, By Patient Type:

    • Dialysis

    • Others

  • Global Chronic Kidney Disease Drugs Market, By Distribution Channel:

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

  • Global Chronic Kidney Disease Drugs Market, By Region:

    • North America

      • By Country:

        • U.S.

        • Canada

    • Latin America

      • By Country:

        • Brazil

        • Mexico

        • Argentina

        • Rest of Latin America

    • Europe

      • By Country:

        • Germany

        • U.K.

        • France

        • Italy

        • Spain

        • Russia

        • Rest of Europe

    • Asia Pacific

      • By Country:

        • China

        • India

        • Japan

        • Australia

        • South Korea

        • ASEAN

        • Rest of Asia Pacific

    • Middle East

      • By Country:

        • GCC

        • Israel

        • Rest of Middle East

    • Africa

      • By Country/Region:

        • South Africa

        • Central Africa

        • North Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201125005473/en/

Contacts

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter